GenMark Diagnostics, Inc. (GNMK)

[BoilerRoom]

$GNMK Winner here

[BoilerRoom]

$GMNK going to run hard folks

[BoilerRoom]

Yes, all in here. Load up buddy

[powerbattles]

$GNMK spike after hours on global shipments of RUO test kits

[BoilerRoom]

$GNMK load up folks

[BoilerRoom]

$GNMK just took starter at $4.00

[whytestocks]

News: $GNMK GenMark Diagnostics to Present at the Bank of America Merrill Lynch Health Care Conference

CARLSBAD, Calif., May 01, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the Bank of America Merrill Lynch Heath Care Conference in L...

Got this from https://marketwirenews.com/news-releases/genmark-diagnostics-to-present-at-the-bank-of-america-merrill-lynch-health-care-conference-8095366.html

[Foodiefor life]

Yay gnmk

[stocktrademan]

GNMK looks like a good one on the 1hr chart with a near stop. It could try to fill that recent gap down or go halfway up on a retrace from the current oversold low. Take a look at CETY it might be making a measured move next week on the daily.

[JohnCM]

BUY with stop loss at $3.99

RSI(14) 8.58 That must be a record.

This report looks good. Not sure about margins. Do not follow this company.

GenMark Diagnostics Reports Third Quarter 2017 Results

Genmark Diagnostics, Inc. (MM) (NASDAQ:GNMK)

Saturday 4 November 2017

GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the third quarter ended September 30, 2017.

Third Quarter Highlights

Placed 65 ePlex® analyzers in the third quarter, mostly driven by first full quarter of U.S. launch

Finished the quarter with an installed base of 147 ePlex analyzers in U.S. and European labs

Achieved revenues of $11.6 million in the quarter, an increase of 7.3% over the prior year period

“We are pleased with our first full quarter of ePlex launch in the U.S., which drove the majority of placements in the third quarter,” said Hany Massarany, President and Chief Executive Officer. “With strong sales funnels and continued positive customer feedback regarding the overall performance of ePlex, we remain optimistic about our opportunity to accelerate our revenue growth rate and capture market share in the global multiplex molecular diagnostics market.”

Third Quarter Financial Results

Revenue was $11.6 million in the third quarter of 2017, an increase of 7.3% versus $10.7 million in the third quarter of 2016. Gross profit was $4.2 million, or 36% of revenue, compared with $6.5 million, or 60% of revenue in the same period of 2016.

Operating expenses for the third quarter of 2017 were $18.9 million compared to $18.1 million in the same period for 2016. The increase was mainly driven by sales and marketing expenses as the Company continues to expand its commercial organization in support of the global ePlex product launch.

Loss per share was $0.28 per share for the third quarter of 2017, compared to a $0.27 loss per share in the third quarter of 2016.

The Company ended the quarter with $86.9 million in cash and investments.

Business Outlook

For full year 2017, GenMark expects revenue to range from $51 - $53 million and gross margin to range from 38% to 40%. The Company expects to exit 2017 with 185-200 ePlex placements.

[ClayTrader]

* * $GNMK Video Chart 11-03-17 * *

Link to Video - click here to watch the technical chart video

[stocktrademan]

GNMK bullish 10.90

analyst upgrade
http://www.google.com/search?q=gnmk&ie=utf-8&oe=utf-8#q=gnmk&tbm=nws



normal chart


log chart

[Pure_Greatness]

$10.56 1,422,000 GIDDY UP

[Pure_Greatness]

$10.31 1,255,0000

[stocktrademan]

$GNMK recent news/filings

turned bullish 7.65
not making lower lows anymore

## source: finance.yahoo.com

Wed, 25 Nov 2015 18:47:00 GMT ~ Do Hedge Funds Love Paratek Pharmaceuticals Inc (PRTK)?


read full: http://www.insidermonkey.com/blog/do-hedge-funds-love-paratek-pharmaceuticals-inc-prtk-389174/
*********************************************************

Mon, 09 Nov 2015 16:21:59 GMT ~ Weekly CFO Buys Highlight: Twitter, GenMark Diagnostics, FireEye


read full: http://finance.yahoo.com/news/weekly-cfo-buys-highlight-twitter-162159554.html
*********************************************************

Sat, 31 Oct 2015 17:04:05 GMT ~ GENMARK DIAGNOSTICS, INC. Financials


read full: http://finance.yahoo.com/q/is?s=gnmk
*********************************************************

Wed, 28 Oct 2015 17:42:26 GMT ~ Why Three Biotech Stocks Are Getting Pounded Alongside A Financial Stock Today


read full: http://www.insidermonkey.com/blog/why-three-biotech-stocks-are-getting-pounded-alongside-a-financial-stock-today-380783/
*********************************************************

Wed, 28 Oct 2015 02:36:26 GMT ~ Edited Transcript of GNMK earnings conference call or presentation 27-Oct-15 8:30pm GMT


read full: http://finance.yahoo.com/news/edited-transcript-gnmk-earnings-conference-023626404.html
*********************************************************

$GNMK charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$GNMK company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/GNMK/company-info
Ticker: $GNMK
OTC Market Place: Not Available
CIK code: not found
Company name: GenMark Diagnostics, Inc.
Incorporated In:

Business Description:

$GNMK share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$GNMK extra dd links

Company name: GenMark Diagnostics, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=GNMK+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=GNMK+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=GNMK+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/GNMK/news - http://finance.yahoo.com/q/h?s=GNMK+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/GNMK/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/GNMK/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=GNMK+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/GNMK
DTCC (dtcc.com): http://search2.dtcc.com/?q=GenMark+Diagnostics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=GenMark+Diagnostics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=GenMark+Diagnostics%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/GNMK
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/GNMK/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/GNMK/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=GNMK&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=GNMK
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/GNMK/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=GNMK+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=GNMK+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=GNMK
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=GNMK
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=GNMK+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/GNMK/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=GNMK+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/GNMK.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=GNMK
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/GNMK/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/GNMK
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/GNMK
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/GNMK:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=GNMK
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=GNMK



$GNMK DD Notes ~ http://www.ddnotesmaker.com/GNMK

[stocktrademan]

$GNMK recent news/filings

bearish 7.105

## source: finance.yahoo.com

Mon, 09 Nov 2015 16:21:59 GMT ~ Weekly CFO Buys Highlight: Twitter, GenMark Diagnostics, FireEye


read full: http://finance.yahoo.com/news/weekly-cfo-buys-highlight-twitter-162159554.html
*********************************************************

Sat, 31 Oct 2015 17:04:05 GMT ~ GENMARK DIAGNOSTICS, INC. Financials


read full: http://finance.yahoo.com/q/is?s=gnmk
*********************************************************

Wed, 28 Oct 2015 17:42:26 GMT ~ Why Three Biotech Stocks Are Getting Pounded Alongside A Financial Stock Today


read full: http://www.insidermonkey.com/blog/why-three-biotech-stocks-are-getting-pounded-alongside-a-financial-stock-today-380783/
*********************************************************

Wed, 28 Oct 2015 02:36:26 GMT ~ Edited Transcript of GNMK earnings conference call or presentation 27-Oct-15 8:30pm GMT


read full: http://finance.yahoo.com/news/edited-transcript-gnmk-earnings-conference-023626404.html
*********************************************************

Tue, 27 Oct 2015 21:19:37 GMT ~ GenMark Diagnostics reports 3Q loss


read full: http://sg.finance.yahoo.com/news/genmark-diagnostics-reports-3q-loss-211937045.html
*********************************************************

$GNMK charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$GNMK company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/GNMK/company-info
Ticker: $GNMK
OTC Market Place: Not Available
CIK code: not found
Company name: GenMark Diagnostics, Inc.
Incorporated In:

Business Description:

$GNMK share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$GNMK extra dd links

Company name: GenMark Diagnostics, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=GNMK+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=GNMK+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=GNMK+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/GNMK/news - http://finance.yahoo.com/q/h?s=GNMK+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/GNMK/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/GNMK/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=GNMK+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/GNMK
DTCC (dtcc.com): http://search2.dtcc.com/?q=GenMark+Diagnostics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=GenMark+Diagnostics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=GenMark+Diagnostics%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/GNMK
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/GNMK/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/GNMK/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=GNMK&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=GNMK
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/GNMK/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=GNMK+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=GNMK+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=GNMK
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=GNMK
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=GNMK+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/GNMK/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=GNMK+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/GNMK.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=GNMK
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/GNMK/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/GNMK/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/GNMK
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/GNMK
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/GNMK:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=GNMK
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=GNMK



$GNMK DD Notes ~ http://www.ddnotesmaker.com/GNMK

[lecorb]

Massarany Hany:Sale 4/09/2015 5,942 $11.52 $68.5K -6.86%

Williams Jennifer Anne

Senior Vice President-Human Resources
Sale 3/13/2015 30,000 $12.56 $376.8K -13.81%

Massarany Hany

President & Chief Executive Officer
Sale 3/09/2015 13,960 $12.06 $168.4K -10.02%

Massarany Hany

President & Chief Executive Officer
Sale 3/11/2015 14,150 $11.71 $165.7K -7.89%

Kayyem Jon Faiz

Senior Vice President-Research & Development
Sale 7/01/2014 6,000 $13.60 $81.6K -20.09%

Massarany Hany

President & Chief Executive Officer
Sale 1/22/2015 5,982 $12.88 $77.0K -17.04%

Williams Jennifer Anne

Senior Vice President-Human Resources
Sale 3/09/2015 6,350 $12.06 $76.6K -10.02%

Gleeson Michael

Sale 3/09/2015 6,105 $12.06 $73.6K -10.02%

Massarany Hany

President & Chief Executive Officer
Sale 7/09/2014 5,964 $11.70 $69.8K -8.04%

Hawkins Jeffrey Alan

Sale 3/09/2015 5,700 $12.06 $68.7K -10.02%

Massarany Hany

President & Chief Executive Officer
Sale 4/09/2015 5,942 $11.52 $68.5K -6.86%

[lecorb]

I do not understand the value of this company.

Benzinga, February 24, 2015

*GenMark Reports Q4 EPS -$0.21 Vs -$0.28, Sales $9.83M Vs Est $9.12M


April 16, 2015, Benzinga
*GenMark Announces Preliminary Q1 Rev. Of $10.1M; FY15 Rev. Between $38-40M
Benzinga

Someone thinks will have a positive EPS?

ResearchTeam: Reduce

TheStreet: Sell

Ford Equity Research: Sell

Jaywalk Consensus: Hold /Sell

My opinion, an overvalued firm

[BostonBull1990]

Can't believe the drop today, I easily see this hitting the $16 price target within the next few months!

[fredugsi]

Big week coming up. Any bets on this stock hitting $14 by Friday? I'm in!

[fredugsi]

Have been buying the stock again for a quick trade. Think in the next couple weeks, this stock could be 20% ++ higher. 1) earnings next week 2) company shows off it's next generation product line up at a major trade show.

[fredugsi]

Stock has had a nice run since the secondary. I'm out at this time, but might be interested in getting re-involved on weakness.

[fredugsi]

7.6 million shares priced at 9.84. That's 1.6 million more than what they advertised!

[biocqr]

GenMark Diagnostics announces public offering of $60 mln of shares of its common stock (9.72 -0.31)

J.P. Morgan Securities LLC will act as sole book-running manager for the proposed offering. The co intends to use the net proceeds from this offering for general corporate purposes, including, but not limited to, the acceleration of its test menu and NexGen platform development, the expansion of its domestic commercial team, the acceleration of its international expansion, increases in administrative infrastructure to support its international and domestic expansion, automation of its manufacturing infrastructure and other working capital requirements.


Read more: http://www.briefing.com/InPlayEq/InPlay/InPlayDual.htm#ixzz2bmzAqNXs
Under Creative Commons License: Attribution

[fredugsi]

Bye bye GNMK! Quarter and guidance not looking good. Lose biggest customer--that's a problem!

[tilong22]

Good call!

[fredugsi]

Bought my original position under $4 years ago. Was first to comment on this stock. I'm OUT! Too many uncertainties with largest customer. Stock headed down to under $8. Be careful my friends!

[mlkrborn]

GenMark Diagnostics sees FY13 revenues of approx $30 mln compared to prior guidance of $35 mln (GNMK) 10.97 -1.00 : As a result of additional uncertainties relating to the future revenue contribution from its largest customer, together with persisting reimbursement and other challenges affecting the emerging pharmacogenomics market sector, the Company is updating its annual revenue guidance to approximately $30 million from its original estimate of approximately $35 million.

"In light of the recent developments which introduced additional uncertainty regarding this customer, we have taken a more conservative outlook and reduced our revenue expectations for the remainder of the year," Massarany further stated. "Nevertheless, we believe the significant growth rates we are experiencing in our core business strengthen our position and support year-over-year growth of about 50%, resulting in approximately $30 million of annual revenue. Furthermore, we continue to make excellent progress toward the development of our NexGen sample-to-answer system, which we believe will fuel significant growth and our future success as a global leader in molecular diagnostics."

[drugtester]

I have been listening to the call and GNMK management is being quite upfront about the NNTK situation and IMO their revised revenue reduction estimates are considerably higher than what we will actually see.

I have been loading the boat from $10.22 to $10.45 and after hearing the details if the call, I have already put in several more orders under $11.00.

This will easily be back close to $14 in short order.

[biocqr]

Notable Calls @thenotablecalls
$GNMK - 'Actual impact to GenMark appears to be minimal,' Canaccord says.

Ian Estepan @ianestepan
Cannacord defending $GNMK saying that after talking to management - $GNMK contract remains intact w NMT w no change to volume commitments

[Realtor417]

In at $11.60 this morning and Out of dip at $13.13 for a nice run up...

[tilong22]

"Term . The initial term of this Agreement shall be for four (4) years, beginning on the Effective Date. Upon expiration of the initial term or any renewal term, this Agreement shall automatically renew for an additional one (1) year period unless either party shall have given the other party written notice of non-renewal at least sixty (60) days prior to expiration of the then-current initial or renewal term. As used herein, “Term” means the initial four year term of this Agreement and, upon renewal hereof in accordance with the foregoing, any such renewal term(s). This Agreement may not be terminated prior to expiration of the then-current Term, except in accordance with the express terms of this Agreement."

From the 10Q. There seems no clause to break the Agreement for first four years. There seems at least three more years before the notice of exiting from the contract.

[biocqr]

GenMark Diagnostics rebounds off lows but remains down over 25% following customer announcement (11.33 -3.80)
GenMark Diagnostics is down over 20% today. This morning Natural Molecular Testing Corporation, a privately-owned company providing clinical diagnostic molecular testing and services in the medical genomics field, announced the launch of their laboratory developed comprehensive Personalized Medicine Panel. This cardiac panel, commercialized by Natural Molecular, is comprised of 42 targets and built using Luminex Corporation's (LMNX) xMAP Technology. This can be seen as a negative to GenMark because Natural Molecular is a large customer for GenMark and some of the Luminex technology may overlap with GenMark's products. In it's most recent 10-Q filing GenMark said, "We have one large customer, Natural Molecular Testing Corporation, which accounted for approximately 62% of our total revenue for the three months ended March 31, 2013. " Analysts at Piper Jaffray noted that GenMark recently signed a 4-year rental deal with Natural Molecular, so it is unclear what impact the Luminex deal will have. More clarity should come tomorrow as the company is scheduled to present at 5:00 p.m. EST at the William Blair 33rd Annual Growth Stock Conference.

Read more: http://www.briefing.com/InPlayEq/InPlay/InPlayDual.htm#ixzz2VvZ9fFml
Under Creative Commons License: Attribution
Follow us: @Briefingcom on Twitter | Briefingcom on Facebook

[Realtor417]

In on this dip at $11.60, looks like a good play....

[biocqr]

Genmark has 7 tests:

Cystic Fibrosis
4-way Thrombophilia
Warfarin Panel
Hep C
RVP - Respiratory Virus Panel
3A4/3A5 (RUO)
2C19 (RUO)

The Luminex PR mentions 4 tests as part of NMT's Personalized Medicine Panel where there is overlap with GNMK... 3a4/3A5 and 2C19 which are both RUO (Research Use Only) so not for commercial use yet... and part of the Warfarin and Thrombophilia panel.

http://www.sacbee.com/2013/06/11/5487682/natural-molecular-testing-corporation.html

Genmark is the largest selling Warfarin panel in the U.S.

NMT is GNMK's biggest customer but the bulk of their revenue is from the RVP test.

[biocqr]

Natural Molecular Testing Corporation Launches an Expanded Personalized Medicine Panel Built on Luminex Corporation's xMAP Technology
Partnership Advances Pharmacogenomics for Improved Patient Care
By Natural Molecular Testing Corporation; Luminex Corporation
Published: Tuesday, Jun. 11, 2013 - 6:13 am

SEATTLE, June 11, 2013 -- /PRNewswire/ -- Natural Molecular Testing Corporation (Natural Molecular, NMTC), a privately-owned company providing groundbreaking clinical diagnostic molecular testing and services in the medical genomics field, announced today the launch of their laboratory developed comprehensive Personalized Medicine Panel. This cardiac panel, commercialized by Natural Molecular, is comprised of 42 targets and built using Luminex Corporation's (NASDAQ: LMNX) xMAP® Technology.

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

"Our goal is to bring the latest advancements in medical science and technology to help clinicians do one simple thing: provide the best possible care for their patients," said Beau R. Fessenden, CEO of Natural Molecular. "By converting to Luminex's xMAP technology, we can improve our throughput and workflow efficiency with more comprehensive and highly sensitive assays that set us apart in the marketplace. The flexibility and high throughput of the Luminex platform combined with the ability to add additional biomarkers make the technology unique and best suited to our expanding needs."

Each year more than 2 million Americans are hospitalized due to adverse drug reactions which lead to an estimated 100,000 deaths.1 Molecular testing allows physicians to diagnose genetic abnormalities in patients, providing guidance in selecting optimal medications and doses of medications while minimizing risk for a wide variety of common conditions such as chronic heart disease and pain.

"We are excited to be expanding our relationship with Natural Molecular in the important area of pharmacogenomics," said Patrick Balthrop, president and CEO of Luminex. "It is valuable for a physician to know whether a specific therapeutic compound will be most beneficial for a particular patient. Through the use of genetic testing, driven by the throughput and scalability of our technology and the unique services of NMTC, our two companies are working together to optimize patient outcomes and lower overall health-care costs. We look forward to expanding opportunities with Natural Molecular, a leader in pharmacogenomic testing."

The financial terms of the multi-year collaboration and license agreement were not disclosed.

About Personalized Medicine Panel Natural Molecular's new comprehensive Personalized Medicine Panel features a simple laboratory workflow based on Luminex's flexible xMAP Technology. Multiplexing a comprehensive set of biomarkers together from a single sample offers significant improvements in testing efficiency saving valuable time and increasing throughput. The panel includes the following:

CYP450 2C19 CYP450 2C9 CYP450 2D6 CYP450 3A4 CYP450 3A5 ABCB1 VKORC1 MTHFR Factor II Factor V Leiden

About Natural Molecular Testing Corporation

Natural Molecular Testing Corporation (NMTC) is a privately-owned, high-complexity molecular testing facility. NMTC provides comprehensive genetic testing solutions that improve patient care through the latest breakthroughs in genomic technology.

For more information about Natural Molecular Testing Corp., visit www.naturalmolecular.com

Read more here: http://www.sacbee.com/2013/06/11/5487682/natural-molecular-testing-corporation.html#storylink=cpy

[biocqr]

Notable Calls @thenotablecalls
$GNMK - My take: This looks like a material negative event for Genmark. Potentially significant downside.
Reply
Retweet
Favorite
More optionsDetails
22m

The Fly on the Wall @theflynews
$LMNX $GNMK Natural Molecular launch a positive for Luminex, says Leerink: Full Story bit.ly/168X46s
Details
stockwhisperer retweeted
22m

Notable Calls @thenotablecalls
$GNMK - Leerink out rather cautious on Genmark after Natural Molecular (~60% of GNMK revs) chose LMNX product over them.
Details
22m

Notable Calls @thenotablecalls
$GNMK - Leerink out rather cautious on Genmark after Natural Molecular (~60% of GNMK revs) chose LMNX product over them.

[fredugsi]

Presentation must not be going well....or a secondary coming? Anyone?

[biocqr]

Genmark presenting at Goldman on June 11 @ 3:20 PM...

http://ir.genmarkdx.com//eventdetail.cfm?eventid=130978

[fredugsi]

Company presenting at Goldman Sachs conference June 11th. Buy stock in quantity NOW! $20 stock by end of July!

[biocqr]

GenMark Diagnostics initiated with an Outperform at Cowen (14.71)

[fredugsi]

BREAKOUT!!

[fredugsi]

Cynical trader...where are you? News is I heard a large hedge fund has initiated a position recently...not through buying!

[fredugsi]

What a move! Any new news?

[fredugsi]

Plus!...company just filed a registration form to possibly sell additional shares. Confusing?!?! I thought last deal they did was their final one.

[fredugsi]

4 execs + gleeson selling stock. Never a good sign. Stock was down over 6% earlier.

[biocqr]

Blowout! $9.4M... 42 analyzers placed, annualized revs/analyzer now $143K

GenMark Exceeds 2012 Revenue Guidance; 2012 Sales Top $20 million
-- Quarterly Reagent Revenue Grows 404% and Annual Reagent Revenue Grows
367%

-- Installed Base Grows to 297 Analyzers

-- Quarterly Gross Margin Reaches 50% and Annual Gross Margin Reaches 43%

-- Annuity Per Analyzer Increased to $143,000

-- FY 2013 Revenue Guidance at $35 Million

CARLSBAD, Calif. --(BUSINESS WIRE)-- March 12, 2013 --
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today reported financial results for the fourth quarter and year ended December 31, 2012 .

Revenues for the quarter ended December 31, 2012 were $9.4 million compared with $2.0 million during the fourth quarter of 2011. The 364% year-over-year increase in quarterly total revenue reflects an increase in the number of systems in the field, growth in test menu and a significant increase in the number of tests sold. Reagent revenues for the fourth quarter grew 404% year- over-year to $9.1 million from $1.8 million . Instrument and other revenues increased by 39% year-over-year to $312,000 from $224,000 due mainly to capital sales of instruments. The Company placed a net of 42 analyzers during the quarter, bringing the installed base to 297 at year end, all in end-user laboratories within the U.S. market.

"Boosted by a more severe than usual flu season, the continued expansion of our installed base and annuity per system enabled our commercial team to close out 2012 with another very robust quarter. This year we will continue to leverage the significant runway still available for our current XT-8 system to maintain this performance trajectory," commented Hany Massarany, GenMark's President and CEO. "We will also continue to focus our R&D organization on completing the development of our NexGen multiplex sample-to-answer system," Mr. Massarany further stated.

Gross profit for the quarter ending December 31, 2012 was $4.7 million , or 50% of sales, compared with a gross profit of $0.4 million , or 20% of sales, for the same period in 2011.
Operating expenses increased $3.5 million to $9.3 million during the fourth quarter of 2012 compared with the fourth quarter of 2011. The increase in operating expenses was across all areas of the Company and reflected higher volumes, increased headcount, infrastructure spending, and product research and development costs.

Loss per share was $0.15 for the fourth quarter of 2012, compared with a loss per share of $0.27 in the fourth quarter of 2011.

For the fiscal year ended December 31, 2012 , total revenue increased 309%, from $5 million in 2011 to $20.5 million in 2012, and gross profit turned from negative $1.2 million to positive $8.8 million for the years ended December 31, 2011 and 2012, respectively. Annual reagent revenues grew 367% year over year to $19.6 million from $4.2 million . The Company placed a net of 130 analyzers during the year, bringing the total installed base to 297, and reagent annuity per analyzer increased from $51,000 to $143,000 .

The Company ended 2012 with $52.6 million in cash, cash equivalents and restricted cash, reflecting the cash proceeds from the follow-on offering completed during the year. The Company intends to continue utilizing its cash balances to invest in new product and menu development, including the development of its NexGen platform, and for infrastructure improvements and general corporate purposes.

For 2013, the Company expects revenue to grow by 70% over 2012 levels to approximately $35 million , with a disproportionate amount of the revenue occurring in the first and fourth quarters of the year due to the seasonality of the Company's Respiratory Viral Panel Test, which is highly utilized during the flu season. In addition, the Company expects to significantly grow the installed base in 2013 by placing in excess of 150 analyzers in customer laboratories. Gross margin is expected to remain just above 50% throughout 2013 with some slight improvements commensurate with anticipated volume growth and quarterly fluctuations due to seasonal volume. Lastly, the Company expects to continue investing in its NexGen platform and menu development in support of its plans for international commercialization by early 2014, and simultaneous FDA submissions for IVD approval and subsequent US launch.

INVESTOR CONFERENCE CALL
GenMark will hold a conference call to discuss the fourth quarter and year end 2012 results at 4:30 PM EDT today. The conference call and webcast can be accessed live through the Company's website under the Investor Relations section and will be archived for future reference. To listen to the conference call, please dial [phone] (US/ Canada ) or [phone] (International) and use the conference ID number 16992443 approximately five minutes prior to the start

[biocqr]

For a comparison... a recap of the 3Q...

$5.3M in sales
35 analyzers sold
reagent revenue 5.1M
.20 loss

[fredugsi]

Time to add to positions before they report after close tomorrow. I'm expecting a BLOW OUT! Stock could have a $14 handle on it come Wed morning!

[fredugsi]

Finally, company comes out with a reporting date for Q4 and year end...Mar 12th